Specifically, the company notes in September 2 statement: "The August 24th communication is part of FDA's current process of sharing information directly with consumers and healthcare professionals related to the safety monitoring of marketed drug products. This does not mean that the FDA has concluded there is a risk."
It also released a statement on August 25.
Alliconnect, a blog for the drug's launch, is no longer available although the print and video statements are also posted to the GSK Web site and the Alli Web site.
Have you registered with us yet?
Register now to enjoy more articles and free email bulletinsRegister